Clinical Trials Logo

B-Cell Malignancies clinical trials

View clinical trials related to B-Cell Malignancies.

Filter by:

NCT ID: NCT01775631 Completed - B-Cell Malignancies Clinical Trials

Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma

Start date: March 2013
Phase: Phase 1
Study type: Interventional

The purpose of the study is to determine the safety, tolerability and maximum tolerated dose of Urelumab in combination with Rituximab in patients with B-cell Non-Hodgkins Lymphoma

NCT ID: NCT00983619 Completed - Cancer Clinical Trials

A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell Malignancies

Start date: April 16, 2010
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the maximum tolerated dose of this drug (MEDI-551) in participants with advanced B-cell malignancies. Expansion to occur at maximum tolerated dose (MTD), or if not reached, at optimal biologic dose (OBD).

NCT ID: NCT00672152 Terminated - Clinical trials for Myelodysplastic Syndrome (MDS)

A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation

WT-1
Start date: June 2007
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety and effectiveness of administering Wilms tumor gene 1 (WT1) cancer peptides. Cancer peptides are short pieces of protein that are made in a laboratory to be like the peptides that can be found in cancer. These peptides are intended to be given as a "vaccine" to activate the immune cells in a person to attack his/her cancer. These peptides are mixed with an oily substance called Montanide ISA-51 and a white cell growth factor called Granulocyte-macrophage colony-stimulating factor (GM-CSF) which may help make the immune response stronger.